Known targets — ChEMBL curated mechanism
SLC6A2SLC6A3SSTR1SSTR2SSTR3SSTR5
The experimentally established mechanism targets of Aspartic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.39 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.37 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.37 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.37 |
| ▸ | GRM8 | O00222 | 1/20 | 0.37 |
| ▸ | GRM6 | O15303 | 1/20 | 0.37 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.37 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.37 |
| ▸ | GSR | P00390 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.37 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.37 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.37 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.37 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aspartic Acid SCHEMBL2728797 | 1.00 | SLC22A6 (0.39) | SLC22A6GABRR1LMNATDP1GRIK1 | |
| Aspartic Acid SCHEMBL1302103 | 0.97 | SLC22A6 (0.38) | SLC22A6GABRR1LMNATDP1GRIK1 | |
| Aspartic Acid SCHEMBL10455864 | 0.97 | SLC22A6 (0.38) | SLC22A6GABRR1LMNATDP1GRIK1 | |
| Aspartic Acid SCHEMBL4018865 | 0.97 | SLC22A6 (0.38) | SLC22A6GABRR1LMNATDP1GRIK1 | |
| Aspartic Acid SCHEMBL17350094 | 0.97 | SLC22A6 (0.38) | SLC22A6GABRR1LMNATDP1GRIK1 | |
| Aspartic Acid SCHEMBL10341216 | 0.97 | SLC22A6 (0.38) | SLC22A6GABRR1LMNATDP1GRIK1 | |
| Aspartic Acid SCHEMBL1938075 | 0.97 | SLC22A6 (0.38) | SLC22A6GABRR1LMNATDP1GRIK1 | |
| Aspartic Acid SCHEMBL1987594 | 0.97 | SLC22A6 (0.41) | SLC22A6GABRR1LMNATDP1GRIK1 | |
| Aspartic Acid SCHEMBL162426 | 0.95 | SLC22A6 (0.39) | SLC22A6GABRR1LMNATDP1GRIK1 | |
| Aspartic Acid SCHEMBL5247248 | 0.95 | SLC22A6 (0.39) | SLC22A6GABRR1LMNATDP1GRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1513 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144835-A1 | MULTIFUNCTIONAL NUTRACEUTICAL FOR ENHANCING FEMALE HEALTH | Beltran, Robert R. (US) | 2026-05-28 | — | — | US | claimed |
| CN-116615180-B | Hydroxyapatite composition for the treatment and/or prevention of viral infections | 库特沃夫博士有限及两合公司 | 2026-05-12 | — | — | CN | claimed |
| EP-4734970-A1 | COMPOSITION COMPRISING HINOKITIOL AND ZINC SALT FOR USE IN THE TREATMENT OF HERPES LABIALIS | AAA Investments B.V. (NL) | 2026-05-06 | — | — | EP | claimed |
| US-12582149-B1 | Functional additive for hot beverages and foods | MILJKOVIC IGOR (US) | 2026-03-24 | — | — | US | claimed |
| EP-4588522-B1 | COMPOSITION FOR TREATMENT AND/OR PREVENTION OF A CORONA VIRUS INFECTION | DR KURT WOLFF GMBH & CO KG (DE) | 2026-01-21 | — | — | EP | claimed |
| EP-4418865-B1 | LIQUID COMPOSITION CONTAINING A COMBINATION OF VITAMINS A, D, E AND K IN A LIQUID MATRIX | LIPOID GMBH (DE) | 2025-12-10 | — | — | EP | claimed |
| EP-4642748-A1 | CROP NUTRITION AND FORTIFICATION COMPOSITION | Bhukhanwala, Komal (IN) | 2025-11-05 | — | — | EP | claimed |
| EP-4642749-A1 | CROP NUTRITION AND FORTIFICATION COMPOSITION | Bhukhanwala, Komal (IN) | 2025-11-05 | — | — | EP | claimed |
| EP-4633395-A1 | MOUTHPIECE FOR AN AEROSOL-GENERATING SYSTEM | Philip Morris Products S.A. (CH) | 2025-10-22 | — | — | EP | claimed |
| EP-4588522-A2 | COMPOSITION FOR TREATMENT AND/OR PREVENTION OF A CORONA VIRUS INFECTION | Dr. Kurt Wolff GmbH & Co. KG (DE) | 2025-07-23 | — | — | EP | claimed |
| EP-0589047-A1 | METHOD OF TREATING INFECTIOUS DISEASE, METHOD OF PREVENTING PUTREFACTION OF COSMETIC, AND ANTIBACTERIAL/ANTIFUNGAL AGENT AND COSMETIC | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-03-30 | — | — | EP | claimed |
| EP-0245669-B1 | Pharmaceutical preparation for preventing damage to living cells by free radicals, or for increasing the efficacy of organic sulphur compounds, and process for increasing the life span of isolated organs | FLOERSHEIM GEORG L (CH) | 1993-12-01 | — | — | EP | claimed |
| EP-0550446-A1 | RADIOPROTECTION BY CALCIUM ANTAGONISTS | BAYER AG (DE) | 1993-07-14 | — | — | EP | claimed |
| WO-1993002670-A1 | RADIOPROTECTION BY CALCIUM ANTAGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 1993-02-18 | — | — | WO | claimed |
| US-5094842-A | Stannous compound for discoloration inhibition | CHESEBROUGH-POND'S USA CO., DIVISION OF CONOPCO, INC. (US) | 1992-03-10 | — | — | US | claimed |
| EP-0152836-B1 | ORAL HYGIENE COMPOSITION | Blendax GmbH (DE) | 1990-06-20 | — | — | EP | claimed |
| US-4719100-A | ZINC OR COPPER ASPARTATE | BLENDAX-WERKE R. SCHNEIDER GMBH & CO. (DE) | 1988-01-12 | — | — | US | claimed |
| US-4698221-A | Vaccines containing fat soluble vitamins, zinc compounds and selenium compounds | BAYER AKTIENGESELLSCHAFT (DE) | 1987-10-06 | — | — | US | claimed |
| EP-0115610-B1 | MEANS FOR FURTHERING PROTEIN SYNTHESIS IN ANIMALS | Dr. Franz Köhler Chemie GmbH (DE) | 1987-06-10 | — | — | EP | claimed |
| US-4622220-A | CONTAINS ZINC OR COPPER ASPARTATE TO CONTROL PLAQUE | BLENDAX-WERKE R. SCHNEIDER (DE) | 1986-11-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12582149-B1 | Functional additive for hot beverages and foods | SOD1, KCNN1, KCNN3 | SLC22A6 1697/4885GABRR1 1403/4885LMNA 4037/4885 |
| US-20260144835-A1 | MULTIFUNCTIONAL NUTRACEUTICAL FOR ENHANCING FEMALE HEALTH | SHBG, MTNR1B, SLC19A2 | SLC22A6 1626/4885GABRR1 116/4885LMNA 1629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.